15811-32-2 Usage
General Description
2-Fluoro-2',3',5'-triacetoxyadenosine is a chemical compound with the molecular formula C14H15FN2O9. It belongs to the category of nucleoside and nucleotide analogues, which are synthetic structures similar to naturally occurring nucleosides. Adenosine analogues, like 2-Fluoro-2',3',5'-triacetoxyadenosine, are often used in medicinal chemistry for their potential pharmacological activities. They are typically used as antiviral or antineoplastic agents. As is common with many complex compounds, this chemical is highly specific and may require detailed study to identify potential interactions, impacts, and uses in different scientific fields. However, detailed information about this particular chemical is limited. It is advisable to handle and use it in controlled environments under specialized expert guidance.
Check Digit Verification of cas no
The CAS Registry Mumber 15811-32-2 includes 8 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 5 digits, 1,5,8,1 and 1 respectively; the second part has 2 digits, 3 and 2 respectively.
Calculate Digit Verification of CAS Registry Number 15811-32:
(7*1)+(6*5)+(5*8)+(4*1)+(3*1)+(2*3)+(1*2)=92
92 % 10 = 2
So 15811-32-2 is a valid CAS Registry Number.
15811-32-2Relevant articles and documents
Nucleic acid related compounds. 34. Non-aqueous diazotization with tert-butyl nitrite. Introduction of fluorine, chlorine, and bromine at C-2 of purine nucleosides
Robins,Uznanski
, p. 2608 - 2611 (1981)
-
Process for the preparation of fludarabine or fludarabine phosphate from guanosine
-
, (2008/06/13)
A process for the production of fludarabine or fludarabine phosphate is provided, wherein the nucleoside guanosine or a suitable derivative is employed as the starting material. The guanosine starting material is subjected to (a) conversion of the 6-keto group into a 6-amino group, (b) conversion of the 2-amino group to a 2-fluoro group, and (c) conversion of the ribofuranosyl moiety to an arabinofuranosyl moiety. Steps (a), (b), and (c) can be performed individually or concomitantly and in any sequence.